ZA201603894B - Cortistatin analogues and syntheses and uses thereof - Google Patents

Cortistatin analogues and syntheses and uses thereof

Info

Publication number
ZA201603894B
ZA201603894B ZA2016/03894A ZA201603894A ZA201603894B ZA 201603894 B ZA201603894 B ZA 201603894B ZA 2016/03894 A ZA2016/03894 A ZA 2016/03894A ZA 201603894 A ZA201603894 A ZA 201603894A ZA 201603894 B ZA201603894 B ZA 201603894B
Authority
ZA
South Africa
Prior art keywords
syntheses
cortistatin analogues
cortistatin
analogues
Prior art date
Application number
ZA2016/03894A
Other languages
English (en)
Inventor
D Shair Matthew
Ramharter Juergen
Efrem Pelish Henry
Bor-Jen Liau Brian
Young Ahn Jae
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of ZA201603894B publication Critical patent/ZA201603894B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2016/03894A 2013-12-24 2016-06-08 Cortistatin analogues and syntheses and uses thereof ZA201603894B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361920674P 2013-12-24 2013-12-24
US201461935240P 2014-02-03 2014-02-03
US201461993329P 2014-05-15 2014-05-15
PCT/US2014/072365 WO2015100420A1 (en) 2013-12-24 2014-12-24 Cortistatin analogues and syntheses and uses thereof

Publications (1)

Publication Number Publication Date
ZA201603894B true ZA201603894B (en) 2018-08-29

Family

ID=52350382

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/03894A ZA201603894B (en) 2013-12-24 2016-06-08 Cortistatin analogues and syntheses and uses thereof

Country Status (30)

Country Link
US (3) US9994582B2 (US07094801-20060822-C00173.png)
EP (2) EP3087080B1 (US07094801-20060822-C00173.png)
JP (2) JP6494631B2 (US07094801-20060822-C00173.png)
KR (1) KR20160101162A (US07094801-20060822-C00173.png)
CN (2) CN110183461A (US07094801-20060822-C00173.png)
AP (1) AP2016009324A0 (US07094801-20060822-C00173.png)
AU (2) AU2014369834B2 (US07094801-20060822-C00173.png)
BR (1) BR112016014760A2 (US07094801-20060822-C00173.png)
CA (1) CA2934819A1 (US07094801-20060822-C00173.png)
CL (1) CL2016001631A1 (US07094801-20060822-C00173.png)
CR (1) CR20160291A (US07094801-20060822-C00173.png)
DO (1) DOP2016000158A (US07094801-20060822-C00173.png)
EA (2) EA030907B1 (US07094801-20060822-C00173.png)
EC (1) ECSP16062174A (US07094801-20060822-C00173.png)
ES (1) ES2709480T3 (US07094801-20060822-C00173.png)
GT (1) GT201600135A (US07094801-20060822-C00173.png)
IL (1) IL246390A0 (US07094801-20060822-C00173.png)
MD (1) MD20160089A2 (US07094801-20060822-C00173.png)
MX (1) MX361652B (US07094801-20060822-C00173.png)
MY (1) MY180383A (US07094801-20060822-C00173.png)
NI (1) NI201600089A (US07094801-20060822-C00173.png)
PE (1) PE20161405A1 (US07094801-20060822-C00173.png)
PH (1) PH12016501258A1 (US07094801-20060822-C00173.png)
RU (1) RU2016126503A (US07094801-20060822-C00173.png)
SA (1) SA516371410B1 (US07094801-20060822-C00173.png)
SG (2) SG10201808151RA (US07094801-20060822-C00173.png)
SV (1) SV2016005234A (US07094801-20060822-C00173.png)
TN (1) TN2016000240A1 (US07094801-20060822-C00173.png)
WO (1) WO2015100420A1 (US07094801-20060822-C00173.png)
ZA (1) ZA201603894B (US07094801-20060822-C00173.png)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087080B1 (en) 2013-12-24 2018-11-28 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
EA031804B1 (ru) 2014-02-03 2019-02-28 Вайтаи Фармасьютиклз, Инк. Дигидропирролопиридиновые ингибиторы ror-гамма
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
JP2018516884A (ja) * 2015-05-08 2018-06-28 プレジデント アンド フェローズ オブ ハーバード カレッジ コルチスタチン誘導体による治療に対する患者の標的化選択
EP3294298A4 (en) * 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
CA3009324A1 (en) * 2015-12-23 2017-06-29 President And Fellows Of Harvard College Cortistatin analogs and uses thereof
EP3394038A4 (en) * 2015-12-23 2019-08-21 President and Fellows of Harvard College TARGETED PATIENT SELECTION FOR TREATMENT WITH SPECIFIC CORTISTANTIDE DERIVATIVES
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ROR-γ調節劑
US20190062340A1 (en) * 2016-02-19 2019-02-28 President And Fellows Of Harward College Cortistatin analogs
WO2018027082A1 (en) * 2016-08-03 2018-02-08 The Broad Institute, Inc. Use of cdk8 inhibitors to treat diseases of inflammation and autoimmunity
JP7142846B2 (ja) 2017-01-30 2022-09-28 国立大学法人京都大学 新規化合物及び制御性t細胞の製造方法
CN107028956A (zh) * 2017-03-06 2017-08-11 刘杰 一种治疗经期抑郁症的药物组合物
AR112461A1 (es) 2017-07-24 2019-10-30 Vitae Pharmaceuticals Inc PROCESOS PARA LA PRODUCCIÓN DE SALES Y FORMAS CRISTALINAS DE INHIBIDORES DE RORg
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
JP7285249B2 (ja) 2017-10-02 2023-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cdk8/cdk19阻害剤としての新規な[1,6]ナフチリジン化合物及び誘導体
AU2020216498A1 (en) * 2019-02-01 2021-09-23 Senex Biotechnology, Inc Bicyclic pyridine compositions and methods of using the same for cancer therapy
WO2023048275A1 (ja) 2021-09-27 2023-03-30 国立大学法人京都大学 T細胞の製造方法
WO2023095802A1 (ja) 2021-11-24 2023-06-01 レグセル株式会社 T細胞関連疾患を治療または予防するための医薬組成物
CA3239019A1 (en) 2021-11-24 2023-06-01 Regcell Co., Ltd. Human inducibility controllable t-cell and method for preparing same

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886589A (en) 1957-08-05 1959-05-12 Merck & Co Inc 8-methyl-5-oxyphenyl hexahydroindan compounds
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5185152A (en) 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL105050A0 (en) 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5554187A (en) 1995-08-18 1996-09-10 Rizzo, Iii; Joseph Medication dispensing intra-ocular lens system
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6074872A (en) 1996-05-15 2000-06-13 The Scripps Research Institute Cortistatin: nucleic acids that encode these neuropeptides
ZA978537B (en) 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
AU5902398A (en) 1996-12-31 1998-07-31 Human Genome Sciences, Inc. Cortistatin polypeptides
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
EP1189922A4 (en) 1999-04-30 2002-08-14 Arch Dev Corp STEROID DERIVATIVES
CA2670236C (en) 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
EP1728797A3 (en) 1999-10-13 2011-03-02 Johns Hopkins University School of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
JP2003512474A (ja) 1999-10-25 2003-04-02 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 血液細胞欠乏症の治療処置
CN1827621A (zh) * 2000-03-31 2006-09-06 萨诺化学药物股份公司 雪花胺的新衍生物和类似物
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
ITMI20011445A1 (it) 2001-07-06 2003-01-06 Europ Geie Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita
AU2003209439A1 (en) 2002-01-30 2003-09-02 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
DE60327946D1 (de) 2002-12-24 2009-07-23 Univ British Columbia Angiogen-wirkende trisulfat steroide und deren verwendung
EP1608671B1 (en) 2003-03-24 2010-01-06 Sterix Limited Oestrogen derivatives as inhibitors of steroid sulphatase
EP1633367A2 (en) 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogenic agents
AU2004259014B2 (en) * 2003-07-24 2009-12-17 Merck Sharp & Dohme Corp. Antibiotic compound
US20070004689A1 (en) 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
GB0421106D0 (en) 2004-09-22 2004-10-27 Sterix Ltd Compound
JP5130453B2 (ja) 2005-03-02 2013-01-30 ユニバーシティ オブ メリーランド,ボルティモア 新規なc−17−ヘテロアリールステロイドcyp17阻害剤/抗アンドロゲン:合成、インビトロ生物活性、薬物動態および抗腫瘍活性
CA2635370A1 (en) 2006-01-09 2007-07-09 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2007082980A1 (es) 2006-01-23 2007-07-26 Consejo Superior De Investigaciones Científicas Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina
WO2007103162A2 (en) 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
WO2007133491A1 (en) * 2006-05-09 2007-11-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
WO2008064425A1 (en) 2006-11-30 2008-06-05 Solbec Pharmaceuticals Limited Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof
KR20090101278A (ko) 2006-12-22 2009-09-24 인더스트리얼 리서치 리미티드 누클레오시다제 및 포스포릴라제 억제제의 아제티딘 유사체
MX2009009429A (es) 2007-03-07 2010-07-05 Infinity Discovery Inc Analogos de ciclopamina lactama y metodos de uso de los mismos.
EP2205074A4 (en) * 2007-10-04 2013-07-31 Harvard College ANALOGUES OF THE MOENOMYCIN, METHODS OF SYNTHESIS AND USES THEREOF
WO2009137335A1 (en) * 2008-05-05 2009-11-12 The Scripps Research Institute Synthesis of (+) corstistatin a and related compounds
WO2010024930A2 (en) * 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
EP2421882A4 (en) 2009-04-22 2013-05-08 Harvard College INHIBITORS OF ANGIOGENESIS
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
CA2799904A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
US8791263B2 (en) 2010-09-17 2014-07-29 Osaka University Cortistatin A analog and use thereof
US20130331414A1 (en) 2011-01-10 2013-12-12 Susana Valente Inhibitors of Retroviral Replication
EA028595B1 (ru) 2012-02-02 2017-12-29 Сенекс Биотекнолоджи Инк. Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака
WO2013122609A1 (en) 2012-02-17 2013-08-22 Genentech, Inc. Methods of using cdk8 antagonists
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
US20160000787A1 (en) 2013-02-26 2016-01-07 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
EP3007686A4 (en) 2013-06-10 2017-03-15 Yeda Research and Development Co., Ltd. Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression
AU2014323131B2 (en) 2013-09-18 2018-08-09 Bcn Peptides S.A. Cortistatin analogues for the treatment of inflammatory and/or immune diseases
EP3087080B1 (en) * 2013-12-24 2018-11-28 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof

Also Published As

Publication number Publication date
BR112016014760A2 (pt) 2017-12-12
SA516371410B1 (ar) 2019-02-13
CA2934819A1 (en) 2015-07-02
CR20160291A (es) 2017-02-24
JP2019108367A (ja) 2019-07-04
TN2016000240A1 (en) 2017-10-06
CL2016001631A1 (es) 2017-02-24
US20190185484A1 (en) 2019-06-20
RU2016126503A3 (US07094801-20060822-C00173.png) 2018-07-17
AP2016009324A0 (en) 2016-07-31
EA030907B1 (ru) 2018-10-31
MX2016008436A (es) 2016-12-16
EP3087080A1 (en) 2016-11-02
DOP2016000158A (es) 2016-10-16
SG10201808151RA (en) 2018-10-30
US20170029435A1 (en) 2017-02-02
AU2014369834B2 (en) 2018-12-20
JP2017509586A (ja) 2017-04-06
MD20160089A2 (ro) 2016-12-31
CN106103452B (zh) 2019-05-21
PH12016501258A1 (en) 2016-08-15
US20180319814A1 (en) 2018-11-08
CN110183461A (zh) 2019-08-30
PE20161405A1 (es) 2017-01-18
GT201600135A (es) 2018-11-27
CN106103452A (zh) 2016-11-09
WO2015100420A1 (en) 2015-07-02
AU2014369834A1 (en) 2016-06-23
SV2016005234A (es) 2018-12-14
MX361652B (es) 2018-12-13
ES2709480T3 (es) 2019-04-16
KR20160101162A (ko) 2016-08-24
EP3087080B1 (en) 2018-11-28
IL246390A0 (en) 2016-08-31
EA201891279A1 (ru) 2019-01-31
EP3505521A1 (en) 2019-07-03
AU2019201888A1 (en) 2019-04-11
ECSP16062174A (es) 2018-12-31
SG11201605178WA (en) 2016-07-28
US9994582B2 (en) 2018-06-12
US10273241B2 (en) 2019-04-30
EA201691167A1 (ru) 2016-11-30
US10508121B2 (en) 2019-12-17
NI201600089A (es) 2016-08-18
RU2016126503A (ru) 2018-01-30
JP6494631B2 (ja) 2019-04-03
MY180383A (en) 2020-11-28

Similar Documents

Publication Publication Date Title
IL246390A0 (en) Analogues of cortistatin, their syntheses and uses
IL274355B (en) Aza-pyridone compounds and their uses
ZA201602510B (en) Strigolactone formulations and uses thereof
SI2968443T1 (sl) Analogi hepcidina in njihova uporaba
EP2997533A4 (en) PUBLICALLY AWARDED ADVERTISING
GB201323008D0 (en) Compounds and uses thereof
GB201418073D0 (en) Fastener
GB201307233D0 (en) Compounds and uses thereof
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
GB201320992D0 (en) Complex and uses thereof
GB201309180D0 (en) Compounds and Their Uses
HK1223307A1 (zh) 新型化合物和其用途
SI3044100T1 (sl) Formatni del in pritrdilo formatnega dela
GB201314610D0 (en) Compounds and their uses
ZA201601880B (en) Hetero-transglycosylase and uses thereof
ZA201601507B (en) Releasable fastener assembly
GB201418529D0 (en) Transformable object
GB2512123B (en) Nozzle
GB201306248D0 (en) Compounds and their uses
GB201301772D0 (en) Fastener
GB2515293B (en) Fastener
GB201323005D0 (en) Compounds and uses thereof
GB201317130D0 (en) Fastener
GB201320161D0 (en) Compounds and their uses
GB201309338D0 (en) Fastener